Optimized treatment strategy for early-stage medium/high-risk hormone receptor-positive/HER2-negative breast cancer
Int J Surg
.
2024 Dec 1;110(12):7590-7592.
doi: 10.1097/JS9.0000000000001779.
Authors
Zhao Bi
1
,
Xiao Sun
1
,
Jia-Xian Zhao
1
,
Peng Chen
1
,
Tian-Yi Wang
2
,
Tong-Yue Ren
1
,
Yong-Sheng Wang
1
Affiliations
1
Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong.
2
Department of Nuclear Medicine, The Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.
PMID:
38869965
PMCID:
PMC11634180
DOI:
10.1097/JS9.0000000000001779
No abstract available